Medical Doctor Program year 2022 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Karen Lytle-Glover

Obstetrics & Gynecology Newark, DE Medical Doctor

NPI 1336168459 CMS profile 241946

4745 Ogletown Stanton Rd, Map1, Suite 207, Newark, DE 19713

Open in the dashboard

General payments

$1,561

90 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$6

6 holdings reported · through program year 2022

Through program year 2022, Karen Lytle-Glover of Newark, DE is reported in the CMS Open Payments database as having received $1,561 across 90 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $6 across 6 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $369 18
2021 General $436 27
2020 General $364 21
2019 General $392 24
2024 Ownership $1 1
2023 Ownership $1 1
2022 Ownership $1 1
2021 Ownership $1 1
2020 Ownership $2 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Lytle-Glover
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Karen Lytle-Glover were reported at $0. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Karen Lytle-Glover Obstetrics & Gynecology median Middle half National median
2019 $392 $172 $62–$391 $163
2020 $364 $94 $36–$222 $114
2021 $436 $136 $42–$369 $132
2022 $369 $160 $50–$433 $149
2023 $0 $169 $56–$423 $160
2024 $0 $152 $50–$371 $164
2025 $0 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $309 21 payments
  2. Daiichi Sankyo Inc. $195 11 payments
  3. Amgen Inc. $158 9 payments
  4. Merck Sharp & Dohme Corporation $99 6 payments
  5. AMAG Pharmaceuticals, Inc. $86 5 payments
  6. Mylan Pharmaceuticals Inc. $80 4 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $75 4 payments
  8. CooperSurgical, Inc. $65 4 payments
  9. Agile Therapeutics, Inc. $65 3 payments
  10. TherapeuticsMD, Inc. $61 3 payments
  11. Other $367 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,475 85 payments
  2. Education $86 5 payments
Products named General payments · program years 2019–2022
  1. Prolia $145 8 payments
  2. EVENITY $132 7 payments
  3. LO LOESTRIN FE $121 9 payments
  4. INJECTAFER Anemia $117 7 payments
  5. ORILISSA $108 7 payments
  6. NEXPLANON $99 6 payments
  7. ORIAHNN $85 6 payments
  8. LILETTA $83 6 payments
  9. INJECTAFER Iron Deficiency Anemia $79 4 payments
  10. MAKENA $71 4 payments
  11. Other $1,140 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Delaware

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record